Endocrinol Metab.  2017 Jun;32(2):200-218. 10.3803/EnM.2017.32.2.200.

Clinical Guidelines for the Management of Adrenal Incidentaloma

Affiliations
  • 1Department of Internal Medicine, St. Paul's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • 2Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • 3Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.
  • 4Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. ykshong@amc.seoul.kr
  • 5Department of Internal Medicine, Soon Chun Hyang University Bucheon Hospital, Soon Chun Hyang University College of Medicine, Bucheon, Korea.
  • 6Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.
  • 7Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
  • 8Department of Internal Medicine, Ajou University School of Medicine, Suwon, Korea.
  • 9Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Korea.
  • 10Department of Internal Medicine, Hallym University Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.
  • 11Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea.
  • 12Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Jinju, Korea.
  • 13Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea. sjyoo@catholic.ac.kr

Abstract

An adrenal incidentaloma is an adrenal mass found in an imaging study performed for other reasons unrelated to adrenal disease and often accompanied by obesity, diabetes, or hypertension. The prevalence and incidence of adrenal incidentaloma increase with age and are also expected to rise due to the rapid development of imaging technology and frequent imaging studies. The Korean Endocrine Society is promoting an appropriate practice guideline to meet the rising incidence of adrenal incidentaloma, in cooperation with the Korean Adrenal Gland and Endocrine Hypertension Study Group. In this paper, we discuss important core issues in managing the patients with adrenal incidentaloma. After evaluating core proposition, we propose the most critical 20 recommendations from the initially organized 47 recommendations by Delphi technique.

Keyword

Adrenal incidentaloma; Adrenal disease; Clinical guideline

MeSH Terms

Adrenal Glands
Delphi Technique
Humans
Hypertension
Incidence
Obesity
Prevalence

Cited by  5 articles

Is Follow-up of Adrenal Incidentalomas Always Mandatory?
Giuseppe Reimondo, Alessandra Muller, Elisa Ingargiola, Soraya Puglisi, Massimo Terzolo
Endocrinol Metab. 2020;35(1):26-35.    doi: 10.3803/EnM.2020.35.1.26.

Percutaneous Adrenal Radiofrequency Ablation: A Short Review for Endocrinologists
Byung Kwan Park
Endocrinol Metab. 2020;35(4):750-755.    doi: 10.3803/EnM.2020.880.

Best Achievements in Pituitary and Adrenal Diseases in 2020
Chang Ho Ahn, Jung Hee Kim
Endocrinol Metab. 2021;36(1):51-56.    doi: 10.3803/EnM.2021.108.

Metabolic Subtyping of Adrenal Tumors: Prospective Multi-Center Cohort Study in Korea
Eu Jeong Ku, Chaelin Lee, Jaeyoon Shim, Sihoon Lee, Kyoung-Ah Kim, Sang Wan Kim, Yumie Rhee, Hyo-Jeong Kim, Jung Soo Lim, Choon Hee Chung, Sung Wan Chun, Soon-Jib Yoo, Ohk-Hyun Ryu, Ho Chan Cho, A Ram Hong, Chang Ho Ahn, Jung Hee Kim, Man Ho Choi
Endocrinol Metab. 2021;36(5):1131-1141.    doi: 10.3803/EnM.2021.1149.

Forty Years Together, New Leap Forward! The 40th Anniversary of the Korean Endocrine Society
Jong Chul Won, Ki-Hyun Baek
Endocrinol Metab. 2022;37(6):851-857.    doi: 10.3803/EnM.2022.604.


Reference

1. Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B. Incidentally discovered adrenal masses. Endocr Rev. 1995; 16:460–484.
2. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev. 2004; 25:309–340.
3. Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000; 85:637–644.
4. Bovio S, Cataldi A, Reimondo G, Sperone P, Novello S, Berruti A, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest. 2006; 29:298–302.
5. Barzon L, Sonino N, Fallo F, Palu G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol. 2003; 149:273–285.
6. Terzolo M, Stigliano A, Chiodini I, Loli P, Furlani L, Arnaldi G, et al. AME position statement on adrenal incidentaloma. Eur J Endocrinol. 2011; 164:851–870.
7. Cawood TJ, Hunt PJ, O'Shea D, Cole D, Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol. 2009; 161:513–527.
8. Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med. 2007; 356:601–610.
9. Frilling A, Tecklenborg K, Weber F, Kuhl H, Muller S, Stamatis G, et al. Importance of adrenal incidentaloma in patients with a history of malignancy. Surgery. 2004; 136:1289–1296.
10. Kim HY, Kim SG, Lee KW, Seo JA, Kim NH, Choi KM, et al. Clinical Study of Adrenal Incidentaloma in Korea. Korean J Intern Med. 2005; 20:303–309.
11. Kim YA, Hwangbo Y, Kim MJ, Choi HJ, Seo JH, Lee Y, et al. Characterization of Incidentally Detected Adrenal Pheochromocytoma. Endocrinol Metab. 2012; 27:132–137.
12. Kim J, Bae KH, Choi YK, Jeong JY, Park KG, Kim JG, et al. Clinical Characteristics for 348 Patients with Adrenal Incidentaloma. Endocrinol Metab. 2013; 28:20–25.
13. Jeong HS, Kim HJ, Kim HS, Kim SW, Shin CS, Park DJ, et al. Clinical Characteristics for 132 Patients with Adrenal Incidentaloma. J Korean Endocr Soc. 2007; 22:260–265.
14. Cho YY, Suh S, Joung JY, Jeong H, Je D, Yoo H, et al. Clinical characteristics and follow-up of Korean patients with adrenal incidentalomas. Korean J Intern Med. 2013; 28:557–564.
15. Libe R, Dall'Asta C, Barbetta L, Baccarelli A, Beck-Peccoz P, Ambrosi B. Long-term follow-up study of patients with adrenal incidentalomas. Eur J Endocrinol. 2002; 147:489–494.
16. Terzolo M, Bovio S, Reimondo G, Pia A, Osella G, Borretta G, et al. Subclinical Cushing's syndrome in adrenal incidentalomas. Endocrinol Metab Clin North Am. 2005; 34:423–439.
17. Fagour C, Bardet S, Rohmer V, Arimone Y, Lecomte P, Valli N, et al. Usefulness of adrenal scintigraphy in the follow-up of adrenocortical incidentalomas: a prospective multicenter study. Eur J Endocrinol. 2009; 160:257–264.
18. Aron D, Terzolo M, Cawood TJ. Adrenal incidentalomas. Best Pract Res Clin Endocrinol Metab. 2012; 26:69–82.
19. Caplan RH, Strutt PJ, Wickus GG. Subclinical hormone secretion by incidentally discovered adrenal masses. Arch Surg. 1994; 129:291–296.
20. Nieman LK. Approach to the patient with an adrenal incidentaloma. J Clin Endocrinol Metab. 2010; 95:4106–4113.
21. Caoili EM, Korobkin M, Francis IR, Cohan RH, Platt JF, Dunnick NR, et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology. 2002; 222:629–633.
22. Zeiger MA, Siegelman SS, Hamrahian AH. Medical and surgical evaluation and treatment of adrenal incidentalomas. J Clin Endocrinol Metab. 2011; 96:2004–2015.
23. Sawka AM, Jaeschke R, Singh RJ, Young WF Jr. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab. 2003; 88:553–558.
24. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016; 101:1889–1916.
25. Oh JY. How to approach and follow adrenal incidentaloma? Korean J Intern Med. 2013; 28:541–543.
26. Kanagarajah P, Ayyathurai R, Manoharan M, Narayanan G, Kava BR. Current concepts in the management of adrenal incidentalomas. Urol Ann. 2012; 4:137–144.
27. Vikram R, Yeung HD, Macapinlac HA, Iyer RB. Utility of PET/CT in differentiating benign from malignant adrenal nodules in patients with cancer. AJR Am J Roentgenol. 2008; 191:1545–1551.
28. Boland GW, Blake MA, Hahn PF, Mayo-Smith WW. Incidental adrenal lesions: principles, techniques, and algorithms for imaging characterization. Radiology. 2008; 249:756–775.
29. Ilias I, Sahdev A, Reznek RH, Grossman AB, Pacak K. The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer. 2007; 14:587–599.
30. Johnson PT, Horton KM, Fishman EK. Adrenal mass imaging with multidetector CT: pathologic conditions, pearls, and pitfalls. Radiographics. 2009; 29:1333–1351.
31. Berruti A, Baudin E, Gelderblom H, Haak HR, Porpiglia F, Fassnacht M, et al. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23:Suppl 7. vii131–vii138.
32. Ansquer C, Scigliano S, Mirallie E, Taieb D, Brunaud L, Sebag F, et al. 18F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicenter evaluation. Eur J Nucl Med Mol Imaging. 2010; 37:1669–1678.
33. Chagpar R, Siperstein AE, Berber E. Adrenocortical cancer update. Surg Clin North Am. 2014; 94:669–687.
34. Allolio B, Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab. 2006; 91:2027–2037.
35. Barzon L, Fallo F, Sonino N, Boscaro M. Development of overt Cushing's syndrome in patients with adrenal incidentaloma. Eur J Endocrinol. 2002; 146:61–66.
36. Angeli A, Osella G, Ali A, Terzolo M. Adrenal incidentaloma: an overview of clinical and epidemiological data from the National Italian Study Group. Horm Res. 1997; 47:279–283.
37. Mazzuco TL, Bourdeau I, Lacroix A. Adrenal incidentalomas and subclinical Cushing's syndrome: diagnosis and treatment. Curr Opin Endocrinol Diabetes Obes. 2009; 16:203–210.
38. Casola G, Nicolet V, vanSonnenberg E, Withers C, Bretagnolle M, Saba RM, et al. Unsuspected pheochromocytoma: risk of blood-pressure alterations during percutaneous adrenal biopsy. Radiology. 1986; 159:733–735.
39. Barzon L, Scaroni C, Sonino N, Fallo F, Gregianin M, Macri C, et al. Incidentally discovered adrenal tumors: endocrine and scintigraphic correlates. J Clin Endocrinol Metab. 1998; 83:55–62.
40. van der Kamp HJ, Wit JM. Neonatal screening for congenital adrenal hyperplasia. Eur J Endocrinol. 2004; 151:Suppl 3. U71–U75.
41. Jaresch S, Kornely E, Kley HK, Schlaghecke R. Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1992; 74:685–689.
42. Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010; 95:4133–4160.
43. Haider MA, Ghai S, Jhaveri K, Lockwood G. Chemical shift MR imaging of hyperattenuating (>10 HU) adrenal masses: does it still have a role? Radiology. 2004; 231:711–716.
44. Ichikawa T, Ohtomo K, Uchiyama G, Fujimoto H, Nasu K. Contrast-enhanced dynamic MRI of adrenal masses: classification of characteristic enhancement patterns. Clin Radiol. 1995; 50:295–300.
45. Heinz-Peer G, Honigschnabl S, Schneider B, Niederle B, Kaserer K, Lechner G. Characterization of adrenal masses using MR imaging with histopathologic correlation. AJR Am J Roentgenol. 1999; 173:15–22.
46. Dunnick NR, Korobkin M. Imaging of adrenal incidentalomas: current status. AJR Am J Roentgenol. 2002; 179:559–568.
47. Groussin L, Bonardel G, Silvera S, Tissier F, Coste J, Abiven G, et al. 18F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients. J Clin Endocrinol Metab. 2009; 94:1713–1722.
48. Tessonnier L, Sebag F, Palazzo FF, Colavolpe C, De Micco C, Mancini J, et al. Does 18F-FDG PET/CT add diagnostic accuracy in incidentally identified non-secreting adrenal tumours. Eur J Nucl Med Mol Imaging. 2008; 35:2018–2025.
49. Blake MA, Slattery JM, Kalra MK, Halpern EF, Fischman AJ, Mueller PR, et al. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy: initial experience. Radiology. 2006; 238:970–977.
50. Caoili EM, Korobkin M, Brown RK, Mackie G, Shulkin BL. Differentiating adrenal adenomas from nonadenomas using (18)F-FDG PET/CT: quantitative and qualitative evaluation. Acad Radiol. 2007; 14:468–475.
51. Nunes ML, Rault A, Teynie J, Valli N, Guyot M, Gaye D, et al. 18F-FDG PET for the identification of adrenocortical carcinomas among indeterminate adrenal tumors at computed tomography scanning. World J Surg. 2010; 34:1506–1510.
52. Bernardino ME, Walther MM, Phillips VM, Graham SD Jr, Sewell CW, Gedgaudas-McClees K, et al. CT-guided adrenal biopsy: accuracy, safety, and indications. AJR Am J Roentgenol. 1985; 144:67–69.
53. Welch TJ, Sheedy PF 2nd, Stephens DH, Johnson CM, Swensen SJ. Percutaneous adrenal biopsy: review of a 10-year experience. Radiology. 1994; 193:341–344.
54. Quayle FJ, Spitler JA, Pierce RA, Lairmore TC, Moley JF, Brunt LM. Needle biopsy of incidentally discovered adrenal masses is rarely informative and potentially hazardous. Surgery. 2007; 142:497–502.
55. Paulsen SD, Nghiem HV, Korobkin M, Caoili EM, Higgins EJ. Changing role of imaging-guided percutaneous biopsy of adrenal masses: evaluation of 50 adrenal biopsies. AJR Am J Roentgenol. 2004; 182:1033–1037.
56. Berland LL, Silverman SG, Gore RM, Mayo-Smith WW, Megibow AJ, Yee J, et al. Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee. J Am Coll Radiol. 2010; 7:754–773.
57. Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev. 1998; 19:647–672.
58. Rossi GP, Pessina AC, Heagerty AM. Primary aldosteronism: an update on screening, diagnosis and treatment. J Hypertens. 2008; 26:613–621.
59. Werbel SS, Ober KP. Pheochromocytoma. Update on diagnosis, localization, and management. Med Clin North Am. 1995; 79:131–153.
60. Eisenhofer G, Goldstein DS, Walther MM, Friberg P, Lenders JW, Keiser HR, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab. 2003; 88:2656–2666.
61. Young WF Jr. Minireview: primary aldosteronism: changing concepts in diagnosis and treatment. Endocrinology. 2003; 144:2208–2213.
62. Chao CT, Wu VC, Kuo CC, Lin YH, Chang CC, Chueh SJ, et al. Diagnosis and management of primary aldosteronism: an updated review. Ann Med. 2013; 45:375–383.
63. Kim BY, Chun AR, Kim KJ, Jung CH, Kang SK, Mok JO, et al. Clinical Characteristics and Metabolic Features of Patients with Adrenal Incidentalomas with or without Subclinical Cushing's Syndrome. Endocrinol Metab (Seoul). 2014; 29:457–463.
64. Giordano R, Marinazzo E, Berardelli R, Picu A, Maccario M, Ghigo E, et al. Long-term morphological, hormonal, and clinical follow-up in a single unit on 118 patients with adrenal incidentalomas. Eur J Endocrinol. 2010; 162:779–785.
65. Tauchmanova L, Rossi R, Biondi B, Pulcrano M, Nuzzo V, Palmieri EA, et al. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab. 2002; 87:4872–4878.
66. Di Dalmazi G, Vicennati V, Rinaldi E, Morselli-Labate AM, Giampalma E, Mosconi C, et al. Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study. Eur J Endocrinol. 2012; 166:669–677.
67. Di Dalmazi G, Vicennati V, Garelli S, Casadio E, Rinaldi E, Giampalma E, et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing’s syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol. 2014; 2:396–405.
68. Debono M, Bradburn M, Bull M, Harrison B, Ross RJ, Newell-Price J. Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. J Clin Endocrinol Metab. 2014; 99:4462–4470.
69. Siren J, Tervahartiala P, Sivula A, Haapiainen R. Natural course of adrenal incidentalomas: seven-year follow-up study. World J Surg. 2000; 24:579–582.
70. Mitchell IC, Auchus RJ, Juneja K, Chang AY, Holt SA, Snyder WH 3rd, et al. “Subclinical Cushing's syndrome” is not subclinical: improvement after adrenalectomy in 9 patients. Surgery. 2007; 142:900–905.
71. Tsuiki M, Tanabe A, Takagi S, Naruse M, Takano K. Cardiovascular risks and their long-term clinical outcome in patients with subclinical Cushing's syndrome. Endocr J. 2008; 55:737–745.
72. Toniato A, Merante-Boschin I, Opocher G, Pelizzo MR, Schiavi F, Ballotta E. Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann Surg. 2009; 249:388–391.
73. Sereg M, Szappanos A, Toke J, Karlinger K, Feldman K, Kaszper E, et al. Atherosclerotic risk factors and complications in patients with non-functioning adrenal adenomas treated with or without adrenalectomy: a long-term follow-up study. Eur J Endocrinol. 2009; 160:647–655.
74. Chiodini I. Clinical review: diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab. 2011; 96:1223–1236.
75. Cui X, Yang L, Li J, Bu S, Wei Q, An Z, et al. Perioperative endocrine therapy for patients with Cushing's syndrome undergoing retroperitoneal laparoscopic adrenalectomy. Int J Endocrinol. 2012; 2012:983965.
76. Davenport E, Lennard T. Acute hypercortisolism: what can the surgeon offer? Clin Endocrinol (Oxf). 2014; 81:498–502.
77. Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, et al. Treatment of Cushing's syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015; 100:2807–2831.
78. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet. 2006; 367:1605–1617.
79. Barash PG, Cullen BF, Stoelting RK. Chapter 41, Anesthesia and the endocrine system. Clinical anesthesia. 4th ed. Philadelphia: Lippincott Williams & Wilkins;2001. p. 1119–1139.
80. Miller RD, Cohen NH, Eriksson LI, Fleisher LA, Wiener-Kronish JP, Young WL. Chapter 39, Anaesthetic implications of concurrent disease. Millers Anaesthesia. 6th ed. Madrid: Elsevier Churchill Livingstone;2005. p. 1156–1225.
81. Boscaro M, Sonino N, Scarda A, Barzon L, Fallo F, Sartori MT, et al. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. J Clin Endocrinol Metab. 2002; 87:3662–3666.
82. Stuijver DJ, van Zaane B, Feelders RA, Debeij J, Cannegieter SC, Hermus AR, et al. Incidence of venous thromboembolism in patients with Cushing’s syndrome: a multicenter cohort study. J Clin Endocrinol Metab. 2011; 96:3525–3532.
83. Zeiger MA, Fraker DL, Pass HI, Nieman LK, Cutler GB Jr, Chrousos GP, et al. Effective reversibility of the signs and symptoms of hypercortisolism by bilateral adrenalectomy. Surgery. 1993; 114:1138–1143.
84. Grossman A, Johannsson G, Quinkler M, Zelissen P. Therapy of endocrine disease: Perspectives on the management of adrenal insufficiency: clinical insights from across Europe. Eur J Endocrinol. 2013; 169:R165–R175.
85. Plouin PF, Duclos JM, Soppelsa F, Boublil G, Chatellier G. Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. J Clin Endocrinol Metab. 2001; 86:1480–1486.
86. Lentschener C, Gaujoux S, Tesniere A, Dousset B. Point of controversy: perioperative care of patients undergoing pheochromocytoma removal-time for a reappraisal? Eur J Endocrinol. 2011; 165:365–373.
87. Lebuffe G, Dosseh ED, Tek G, Tytgat H, Moreno S, Tavernier B, et al. The effect of calcium channel blockers on outcome following the surgical treatment of phaeochromocytomas and paragangliomas. Anaesthesia. 2005; 60:439–444.
88. Perry RR, Keiser HR, Norton JA, Wall RT, Robertson CN, Travis W, et al. Surgical management of pheochromocytoma with the use of metyrosine. Ann Surg. 1990; 212:621–628.
89. Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab. 2007; 92:4069–4079.
90. Grosse H, Schroder D, Schober O, Hausen B, Dralle H. The importance of high-dose alpha-receptor blockade for blood volume and hemodynamics in pheochromocytoma. Anaesthesist. 1990; 39:313–318.
91. Mannelli M. Management and treatment of pheochromocytomas and paragangliomas. Ann N Y Acad Sci. 2006; 1073:405–416.
92. Williams DT, Dann S, Wheeler MH. Phaeochromocytoma: views on current management. Eur J Surg Oncol. 2003; 29:483–490.
93. Bravo EL. Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocr Rev. 1994; 15:356–368.
94. Agarwal G, Sadacharan D, Aggarwal V, Chand G, Mishra A, Agarwal A, et al. Surgical management of organ-contained unilateral pheochromocytoma: comparative outcomes of laparoscopic and conventional open surgical procedures in a large single-institution series. Langenbecks Arch Surg. 2012; 397:1109–1116.
95. Shen WT, Grogan R, Vriens M, Clark OH, Duh QY. One hundred two patients with pheochromocytoma treated at a single institution since the introduction of laparoscopic adrenalectomy. Arch Surg. 2010; 145:893–897.
96. Dickson PV, Alex GC, Grubbs EG, Ayala-Ramirez M, Jimenez C, Evans DB, et al. Posterior retroperitoneoscopic adrenalectomy is a safe and effective alternative to transabdominal laparoscopic adrenalectomy for pheochromocytoma. Surgery. 2011; 150:452–458.
97. Walz MK, Alesina PF, Wenger FA, Koch JA, Neumann HP, Petersenn S, et al. Laparoscopic and retroperitoneoscopic treatment of pheochromocytomas and retroperitoneal paragangliomas: results of 161 tumors in 126 patients. World J Surg. 2006; 30:899–908.
98. Kinney MA, Narr BJ, Warner MA. Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth. 2002; 16:359–369.
99. Amar L, Fassnacht M, Gimenez-Roqueplo AP, Januszewicz A, Prejbisz A, Timmers H, et al. Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma. Horm Metab Res. 2012; 44:385–389.
100. Harris DA, Au-Yong I, Basnyat PS, Sadler GP, Wheeler MH. Review of surgical management of aldosterone secreting tumours of the adrenal cortex. Eur J Surg Oncol. 2003; 29:467–474.
101. Sywak M, Pasieka JL. Long-term follow-up and cost benefit of adrenalectomy in patients with primary hyperaldosteronism. Br J Surg. 2002; 89:1587–1593.
102. Reimel B, Zanocco K, Russo MJ, Zarnegar R, Clark OH, Allendorf JD, et al. The management of aldosterone-producing adrenal adenomas: does adrenalectomy increase costs? Surgery. 2010; 148:1178–1185.
103. Parthasarathy HK, Menard J, White WB, Young WF Jr, Williams GH, Williams B, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011; 29:980–990.
104. Karagiannis A, Tziomalos K, Papageorgiou A, Kakafika AI, Pagourelias ED, Anagnostis P, et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother. 2008; 9:509–515.
105. Reincke M, Fischer E, Gerum S, Merkle K, Schulz S, Pallauf A, et al. Observational study mortality in treated primary aldosteronism: the German Conn's registry. Hypertension. 2012; 60:618–624.
106. Mattsson C, Young WF Jr. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol. 2006; 2:198–208.
107. Fischer E, Hanslik G, Pallauf A, Degenhart C, Linsenmaier U, Beuschlein F, et al. Prolonged zona glomerulosa insufficiency causing hyperkalemia in primary aldosteronism after adrenalectomy. J Clin Endocrinol Metab. 2012; 97:3965–3973.
108. Lenert JT, Barnett CC Jr, Kudelka AP, Sellin RV, Gagel RF, Prieto VG, et al. Evaluation and surgical resection of adrenal masses in patients with a history of extra-adrenal malignancy. Surgery. 2001; 130:1060–1067.
109. Zeiger MA, Thompson GB, Duh QY, Hamrahian AH, Angelos P, Elaraj D, et al. American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the Management of Adrenal Incidentalomas: executive summary of recommendations. Endocr Pract. 2009; 15:450–453.
110. Kapoor A, Morris T, Rebello R. Guidelines for the management of the incidentally discovered adrenal mass. Can Urol Assoc J. 2011; 5:241–247.
111. Szolar DH, Korobkin M, Reittner P, Berghold A, Bauernhofer T, Trummer H, et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology. 2005; 234:479–485.
112. Fishman EK, Deutch BM, Hartman DS, Goldman SM, Zerhouni EA, Siegelman SS. Primary adrenocortical carcinoma: CT evaluation with clinical correlation. AJR Am J Roentgenol. 1987; 148:531–535.
113. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014; 99:1915–1942.
114. Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016; 175:G1–G34.
115. Pantalone KM, Gopan T, Remer EM, Faiman C, Ioachimescu AG, Levin HS, et al. Change in adrenal mass size as a predictor of a malignant tumor. Endocr Pract. 2010; 16:577–587.
116. Kannan S, Remer EM, Hamrahian AH. Evaluation of patients with adrenal incidentalomas. Curr Opin Endocrinol Diabetes Obes. 2013; 20:161–169.
117. Vassilatou E, Vryonidou A, Michalopoulou S, Manolis J, Caratzas J, Phenekos C, et al. Hormonal activity of adrenal incidentalomas: results from a long-term follow-up study. Clin Endocrinol (Oxf). 2009; 70:674–679.
Full Text Links
  • ENM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr